Browsing Tag
Vabysmo
7 posts
Ligand Pharmaceuticals (LGND) to acquire XOMA Royalty (XOMA) for $739m as biotech royalty consolidation accelerates
Ligand is buying XOMA for $739 million in cash. The real story sits inside a CVR tied to a $19.7 billion Johnson and Johnson royalty fight.
Why Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) just strengthened the Eylea HD case against Roche’s Vabysmo
Regeneron won FDA approval for every-20-week Eylea HD dosing in wet AMD and DME. Read what it means for Regeneron, rivals, and retinal drug markets.
A new Vabysmo challenger? Innovent Biologics’ IBI324 just made the retinal drug race more interesting
Innovent Biologics is advancing IBI324 into Phase 3 after new retinal disease data versus Vabysmo. Read what it could mean for ophthalmology now.
Vabysmo shows 4-year durability in wet AMD and 60% lesion clearance in PCV: What the new Genentech data reveals
Genentech’s Vabysmo shows four years of vision durability in AMD and strong lesion control in PCV—see what’s next for this bispecific breakthrough.
FDA approves Roche’s Vabysmo prefilled syringe for eye diseases, expanding treatment options for millions
Roche (SIX: RO, ROG; OTCQX: RHHBY), a global leader in pharmaceuticals and diagnostics, announced a significant advancement in…
FDA approves Genentech’s Vabysmo prefilled syringe for eye diseases
In a significant advancement in the treatment of eye diseases, the U.S. Food and Drug Administration (FDA) has…
Roche’s Vabysmo gains FDA approval for treating retinal vein occlusion
Pharma giant Roche has secured the U.S. FDA’s approval for Vabysmo (faricimab) in treating macular edema after retinal…